<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36591311</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>18</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Markers of blood-brain barrier disruption increase early and persistently in COVID-19 patients with neurological manifestations.</ArticleTitle><Pagination><StartPage>1070379</StartPage><MedlinePgn>1070379</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1070379</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2022.1070379</ELocationID><Abstract><AbstractText Label="BACKGROUND">Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 infection is associated with disorders affecting the peripheral and the central nervous system. A high number of patients develop post-COVID-19 syndrome with the persistence of a large spectrum of symptoms, including neurological, beyond 4 weeks after infection. Several potential mechanisms in the acute phase have been hypothesized, including damage of the blood-brain-barrier (BBB). We tested weather markers of BBB damage in association with markers of brain injury and systemic inflammation may help in identifying a blood signature for disease severity and neurological complications.</AbstractText><AbstractText Label="METHODS">Blood biomarkers of BBB disruption (MMP-9, GFAP), neuronal damage (NFL) and systemic inflammation (PPIA, IL-10, TNF&#x3b1;) were measured in two COVID-19 patient cohorts with high disease severity (ICUCovid; n=79) and with neurological complications (NeuroCovid; n=78), and in two control groups free from COVID-19 history, healthy subjects (n=20) and patients with amyotrophic lateral sclerosis (ALS; n=51). Samples from COVID-19 patients were collected during the first and the second wave of COVID-19 pandemic in Lombardy, Italy. Evaluations were done at acute and chronic phases of the COVID-19 infection.</AbstractText><AbstractText Label="RESULTS">Blood biomarkers of BBB disruption and neuronal damage are high in COVID-19 patients with levels similar to or higher than ALS. NeuroCovid patients display lower levels of the cytokine storm inducer PPIA but higher levels of MMP-9 than ICUCovid patients. There was evidence of different temporal dynamics in ICUCovid compared to NeuroCovid patients with PPIA and IL-10 showing the highest levels in ICUCovid patients at acute phase. On the contrary, MMP-9 was higher at acute phase in NeuroCovid patients, with a severity dependency in the long-term. We also found a clear severity dependency of NFL and GFAP levels, with deceased patients showing the highest levels.</AbstractText><AbstractText Label="DISCUSSION">The overall picture points to an increased risk for neurological complications in association with high levels of biomarkers of BBB disruption. Our observations may provide hints for therapeutic approaches mitigating BBB disruption to reduce the neurological damage in the acute phase and potential dysfunction in the long-term.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Bonetto, Pasetto, Lisi, Carbonara, Zangari, Ferrari, Punzi, Luotti, Bottino, Biagianti, Moglia, Fuda, Gualtierotti, Blasi, Canetta, Montano, Tettamanti, Camera, Grimoldi, Negro, Rifino, Calvo, Brambilla, Biroli, Bandera, Nobili, Stocchetti, Sessa and Zanier.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bonetto</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasetto</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lisi</LastName><ForeName>Ilaria</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carbonara</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zangari</LastName><ForeName>Rosalia</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrari</LastName><ForeName>Erica</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Punzi</LastName><ForeName>Veronica</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luotti</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bottino</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biagianti</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moglia</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>"Rita Levi Montalcini", Department of Neuroscience, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>AOU Citt&#xe0; della Salute e della Scienza Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuda</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>"Rita Levi Montalcini", Department of Neuroscience, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gualtierotti</LastName><ForeName>Roberta</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blasi</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Canetta</LastName><ForeName>Ciro</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montano</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tettamanti</LastName><ForeName>Mauro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Camera</LastName><ForeName>Giorgia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, Papa Giovanni XXIII Hospital, ASST Papa Giovanni XXIII, Bergamo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grimoldi</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Papa Giovanni XXIII Hospital, ASST Papa Giovanni XXIII, Bergamo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Negro</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Neurology Section, School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rifino</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Neurology, University of Milano-Bicocca, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calvo</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>"Rita Levi Montalcini", Department of Neuroscience, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>AOU Citt&#xe0; della Salute e della Scienza Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brambilla</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biroli</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bandera</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nobili</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stocchetti</LastName><ForeName>Nino</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sessa</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Papa Giovanni XXIII Hospital, ASST Papa Giovanni XXIII, Bergamo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zanier</LastName><ForeName>Elisa R</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>130068-27-8</RegistryNumber><NameOfSubstance UI="D016753">Interleukin-10</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.35</RegistryNumber><NameOfSubstance UI="D020780">Matrix Metalloproteinase 9</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016753" MajorTopicYN="N">Interleukin-10</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020780" MajorTopicYN="N">Matrix Metalloproteinase 9</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009422" MajorTopicYN="Y">Nervous System Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">blood biomarkers</Keyword><Keyword MajorTopicYN="N">blood-brain barrier</Keyword><Keyword MajorTopicYN="N">critical care</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">neurological damages</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>2</Day><Hour>4</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36591311</ArticleId><ArticleId IdType="pmc">PMC9798841</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2022.1070379</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ren AL, Digby RJ, Needham EJ. Neurological update: COVID-19. J Neurol (2021) 268:4379&#x2013;87. doi:&#xa0;10.1007/s00415-021-10581-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-021-10581-y</ArticleId><ArticleId IdType="pmc">PMC8085652</ArticleId><ArticleId IdType="pubmed">33929617</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehandru S, Merad M. Pathological sequelae of long-haul COVID. Nat Immunol (2022) 23:194&#x2013;202. doi:&#xa0;10.1038/s41590-021-01104-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01104-y</ArticleId><ArticleId IdType="pmc">PMC9127978</ArticleId><ArticleId IdType="pubmed">35105985</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitaker M, Elliott J, Chadeau-Hyam M, Riley S, Darzi A, Cooke G, et al. . Persistent COVID-19 symptoms in a community study of 606,434 people in England. Nat Commun (2022) 13:1957. doi:&#xa0;10.1038/s41467-022-29521-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-29521-z</ArticleId><ArticleId IdType="pmc">PMC9005552</ArticleId><ArticleId IdType="pubmed">35413949</ArticleId></ArticleIdList></Reference><Reference><Citation>Mannucci PM, Nobili A, Tettamanti M, D&#x2019;Avanzo B, Galbussera AA, Remuzzi G, et al. . Impact of the post-COVID-19 condition on health care after the first disease wave in Lombardy. J Intern Med (2022) 292(3):450&#x2013;62. doi:&#xa0;10.1111/joim.13493</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.13493</ArticleId><ArticleId IdType="pmc">PMC9115275</ArticleId><ArticleId IdType="pubmed">35373863</ArticleId></ArticleIdList></Reference><Reference><Citation>Voruz P, Allali G, Benzakour L, Nuber-Champier A, Thomasson M, Jacot I, et al. . Long COVID neuropsychological deficits after severe, moderate or mild infection. Clinical and Translational Neuroscience (2022) 6(2):9. doi:&#xa0;10.3390/ctn6020009</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ctn6020009</ArticleId></ArticleIdList></Reference><Reference><Citation>Magn&#xfa;sd&#xf3;ttir I, Lovik A, Unnarsd&#xf3;ttir AB, McCartney D, Ask H, K&#xf5;iv K, et al. . Acute COVID-19 severity and mental health morbidity trajectories in patient populations of six nations: an observational study. Lancet Public Health (2022) 7:e406&#x2013;16. doi:&#xa0;10.1016/S2468-2667(22)00042-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-2667(22)00042-1</ArticleId><ArticleId IdType="pmc">PMC8920517</ArticleId><ArticleId IdType="pubmed">35298894</ArticleId></ArticleIdList></Reference><Reference><Citation>Zayet S, Zahra H, Royer P-Y, Tipirdamaz C, Mercier J, Gendrin V, et al. . Post-COVID-19 syndrome: Nine months after SARS-CoV-2 infection in a cohort of 354 patients: Data from the first wave of COVID-19 in nord franche-comt&#xe9; hospital, France. Microorganisms (2021) 9(8):1719. doi:&#xa0;10.3390/microorganisms9081719</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms9081719</ArticleId><ArticleId IdType="pmc">PMC8401026</ArticleId><ArticleId IdType="pubmed">34442798</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik P, Patel K, Pinto C, Jaiswal R, Tirupathi R, Pillai S, et al. . Post-acute COVID-19 syndrome (PCS) and health-related quality of life (HRQoL)-a systematic review and meta-analysis. J Med Virol (2022) 94:253&#x2013;62. doi:&#xa0;10.1002/jmv.27309</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27309</ArticleId><ArticleId IdType="pmc">PMC8662132</ArticleId><ArticleId IdType="pubmed">34463956</ArticleId></ArticleIdList></Reference><Reference><Citation>Aamodt AH, H&#xf8;gest&#xf8;l EA, Popperud TH, Holter JC, Dyrhol-Riise AM, Tonby K, et al. . Blood neurofilament light concentration at admittance: a potential prognostic marker in COVID-19. J Neurol (2021) 268:3574&#x2013;83. doi:&#xa0;10.1007/s00415-021-10517-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-021-10517-6</ArticleId><ArticleId IdType="pmc">PMC7980743</ArticleId><ArticleId IdType="pubmed">33743046</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanberg N, Ashton NJ, Andersson L-M, Yilmaz A, Lindh M, Nilsson S, et al. . Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19. Neurology (2020) 95:e1754&#x2013;9. doi:&#xa0;10.1212/WNL.0000000000010111</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000010111</ArticleId><ArticleId IdType="pubmed">32546655</ArticleId></ArticleIdList></Reference><Reference><Citation>Needham EJ, Ren AL, Digby RJ, Norton EJ, Ebrahimi S, Outtrim JG, et al. . Brain injury in COVID-19 is associated with dysregulated innate and adaptive immune responses. Brain (2022) 145(11):4097&#x2013;107. doi:&#xa0;10.1093/brain/awac321</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awac321</ArticleId><ArticleId IdType="pmc">PMC9494359</ArticleId><ArticleId IdType="pubmed">36065116</ArticleId></ArticleIdList></Reference><Reference><Citation>Beghi E, Helbok R, Ozturk S, Karadas O, Lisnic V, Grosu O, et al. . Short- and long-term outcome and predictors in an international cohort of patients with neuro-COVID-19. Eur J Neurol (2022) 29:1663&#x2013;84. doi:&#xa0;10.1111/ene.15293</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.15293</ArticleId><ArticleId IdType="pmc">PMC9111799</ArticleId><ArticleId IdType="pubmed">35194889</ArticleId></ArticleIdList></Reference><Reference><Citation>Balcom EF, Nath A, Power C. Acute and chronic neurological disorders in COVID-19: potential mechanisms of disease. Brain (2021) 144:3576&#x2013;88. doi:&#xa0;10.1093/brain/awab302</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab302</ArticleId><ArticleId IdType="pmc">PMC8719840</ArticleId><ArticleId IdType="pubmed">34398188</ArticleId></ArticleIdList></Reference><Reference><Citation>Erickson MA, Rhea EM, Knopp RC, Banks WA. Interactions of SARS-CoV-2 with the blood-brain barrier. Int J Mol Sci (2021) 22(5):2681. doi:&#xa0;10.3390/ijms22052681</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22052681</ArticleId><ArticleId IdType="pmc">PMC7961671</ArticleId><ArticleId IdType="pubmed">33800954</ArticleId></ArticleIdList></Reference><Reference><Citation>Butsabong T, Felippe M, Campagnolo P, Maringer K. The emerging role of perivascular cells (pericytes) in viral pathogenesis. J Gen Virol (2021) 102(8):001634. doi:&#xa0;10.1099/jgv.0.001634</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jgv.0.001634</ArticleId><ArticleId IdType="pmc">PMC8513640</ArticleId><ArticleId IdType="pubmed">34424156</ArticleId></ArticleIdList></Reference><Reference><Citation>Underly RG, Levy M, Hartmann DA, Grant RI, Watson AN, Shih AY. Pericytes as inducers of rapid, matrix metalloproteinase-9-Dependent capillary damage during ischemia. J Neurosci (2017) 37:129&#x2013;40. doi:&#xa0;10.1523/JNEUROSCI.2891-16.2016</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2891-16.2016</ArticleId><ArticleId IdType="pmc">PMC5214626</ArticleId><ArticleId IdType="pubmed">28053036</ArticleId></ArticleIdList></Reference><Reference><Citation>Takata F, Dohgu S, Matsumoto J, Takahashi H, Machida T, Wakigawa T, et al. . Brain pericytes among cells constituting the blood-brain barrier are highly sensitive to tumor necrosis factor-&#x3b1;, releasing matrix metalloproteinase-9 and migrating. vitro. J Neuroinflamm (2011) 8:106. doi:&#xa0;10.1186/1742-2094-8-106</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-8-106</ArticleId><ArticleId IdType="pmc">PMC3182916</ArticleId><ArticleId IdType="pubmed">21867555</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Estrada EY, Thompson JF, Liu W, Rosenberg GA. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab (2007) 27:697&#x2013;709. doi:&#xa0;10.1038/sj.jcbfm.9600375</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.jcbfm.9600375</ArticleId><ArticleId IdType="pubmed">16850029</ArticleId></ArticleIdList></Reference><Reference><Citation>Barr TL, Latour LL, Lee K-Y, Schaewe TJ, Luby M, Chang GS, et al. . Blood-brain barrier disruption in humans is independently associated with increased matrix metalloproteinase-9. Stroke (2010) 41:e123&#x2013;128. doi:&#xa0;10.1161/STROKEAHA.109.570515</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.109.570515</ArticleId><ArticleId IdType="pmc">PMC2827673</ArticleId><ArticleId IdType="pubmed">20035078</ArticleId></ArticleIdList></Reference><Reference><Citation>Weekman EM, Wilcock DM. Matrix metalloproteinase in blood-brain barrier breakdown in dementia. J Alzheimers Dis (2016) 49:893&#x2013;903. doi:&#xa0;10.3233/JAD-150759</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-150759</ArticleId><ArticleId IdType="pubmed">26599057</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, Wu Z, et al. . Apolipoprotein e controls cerebrovascular integrity via cyclophilin a. Nature (2012) 485:512&#x2013;6. doi:&#xa0;10.1038/nature11087</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11087</ArticleId><ArticleId IdType="pmc">PMC4047116</ArticleId><ArticleId IdType="pubmed">22622580</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasetto L, Pozzi S, Castelnovo M, Basso M, Estevez AG, Fumagalli S, et al. . Targeting extracellular cyclophilin a reduces neuroinflammation and extends survival in a mouse model of amyotrophic lateral sclerosis. J Neurosci (2017) 37:1413&#x2013;27. doi:&#xa0;10.1523/JNEUROSCI.2462-16.2016</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2462-16.2016</ArticleId><ArticleId IdType="pmc">PMC6705677</ArticleId><ArticleId IdType="pubmed">28011744</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K, Chen W, Zhang Z, Deng Y, Lian J-Q, Du P, et al. . CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. Signal Trans Target Ther (2020) 5:283. doi:&#xa0;10.1038/s41392-020-00426-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-00426-x</ArticleId><ArticleId IdType="pmc">PMC7714896</ArticleId><ArticleId IdType="pubmed">33277466</ArticleId></ArticleIdList></Reference><Reference><Citation>Geng J, Chen L, Yuan Y, Wang K, Wang Y, Qin C, et al. . CD147 antibody specifically and effectively inhibits infection and cytokine storm of SARS-CoV-2 and its variants delta, alpha, beta, and gamma. Signal Trans Target Ther (2021) 6:347. doi:&#xa0;10.1038/s41392-021-00760-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00760-8</ArticleId><ArticleId IdType="pmc">PMC8464593</ArticleId><ArticleId IdType="pubmed">34564690</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelhak A, Foschi M, Abu-Rumeileh S, Yue JK, D&#x2019;Anna L, Huss A, et al. . Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat Rev Neurol (2022) 18:158&#x2013;72. doi:&#xa0;10.1038/s41582-021-00616-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-021-00616-3</ArticleId><ArticleId IdType="pubmed">35115728</ArticleId></ArticleIdList></Reference><Reference><Citation>Rifino N, Censori B, Agazzi E, Alimonti D, Bonito V, Camera G, et al. . Neurologic manifestations in 1760 COVID-19 patients admitted to papa Giovanni XXIII hospital, bergamo, Italy. J Neurol (2021) 268:2331&#x2013;8. doi:&#xa0;10.1007/s00415-020-10251-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-10251-5</ArticleId><ArticleId IdType="pmc">PMC7539268</ArticleId><ArticleId IdType="pubmed">33026520</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJB, Culebras A, et al. . An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American heart Association/American stroke association. Stroke (2013) 44:2064&#x2013;89. doi:&#xa0;10.1161/STR.0b013e318296aeca</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STR.0b013e318296aeca</ArticleId><ArticleId IdType="pubmed">23652265</ArticleId></ArticleIdList></Reference><Reference><Citation>Sejvar JJ, Kohl KS, Gidudu J, Amato A, Bakshi N, Baxter R, et al. . Guillain-Barr&#xe9; Syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine (2011) 29:599&#x2013;612. doi:&#xa0;10.1016/j.vaccine.2010.06.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2010.06.003</ArticleId><ArticleId IdType="pubmed">20600491</ArticleId></ArticleIdList></Reference><Reference><Citation>Quist-Paulsen E, Kran A-MB, Lindland ES, Ellefsen K, Sandvik L, Dunlop O, et al. . To what extent can clinical characteristics be used to distinguish encephalitis from encephalopathy of other causes? results from a prospective observational study. BMC Infect Dis (2019) 19:80. doi:&#xa0;10.1186/s12879-018-3570-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-018-3570-2</ArticleId><ArticleId IdType="pmc">PMC6343342</ArticleId><ArticleId IdType="pubmed">30669985</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfefferle S, Sch&#xf6;pf J, K&#xf6;gl M, Friedel CC, M&#xfc;ller MA, Carbajo-Lozoya J, et al. . The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors. PloS Pathog (2011) 7:e1002331. doi:&#xa0;10.1371/journal.ppat.1002331</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1002331</ArticleId><ArticleId IdType="pmc">PMC3203193</ArticleId><ArticleId IdType="pubmed">22046132</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghezzi P, Casagrande S, Massignan T, Basso M, Bellacchio E, Mollica L, et al. . Redox regulation of cyclophilin a by glutathionylation. Proteomics (2006) 6:817&#x2013;25. doi:&#xa0;10.1002/pmic.200500177</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pmic.200500177</ArticleId><ArticleId IdType="pubmed">16372262</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratelli M, Demol H, Puype M, Casagrande S, Eberini I, Salmona M, et al. . Identification by redox proteomics of glutathionylated proteins in oxidatively stressed human T lymphocytes. Proc Natl Acad Sci U.S.A. (2002) 99:3505&#x2013;10. doi:&#xa0;10.1073/pnas.052592699</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.052592699</ArticleId><ArticleId IdType="pmc">PMC122553</ArticleId><ArticleId IdType="pubmed">11904414</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherry B, Yarlett N, Strupp A, Cerami A. Identification of cyclophilin as a proinflammatory secretory product of lipopolysaccharide-activated macrophages. Proc Natl Acad Sci U.S.A. (1992) 89:3511&#x2013;5. doi:&#xa0;10.1073/pnas.89.8.3511</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.89.8.3511</ArticleId><ArticleId IdType="pmc">PMC48898</ArticleId><ArticleId IdType="pubmed">1565646</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh K, Nigro P, Matoba T, O&#x2019;Dell MR, Cui Z, Shi X, et al. . Cyclophilin a enhances vascular oxidative stress and the development of angiotensin II-induced aortic aneurysms. Nat Med (2009) 15:649&#x2013;56. doi:&#xa0;10.1038/nm.1958</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1958</ArticleId><ArticleId IdType="pmc">PMC2704983</ArticleId><ArticleId IdType="pubmed">19430489</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H, Kim WJ, Jeon ST, Koh EM, Cha HS, Ahn KS, et al. . Cyclophilin a may contribute to the inflammatory processes in rheumatoid arthritis through induction of matrix degrading enzymes and inflammatory cytokines from macrophages. Clin Immunol (2005) 116:217&#x2013;24. doi:&#xa0;10.1016/j.clim.2005.05.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2005.05.004</ArticleId><ArticleId IdType="pubmed">15993649</ArticleId></ArticleIdList></Reference><Reference><Citation>Nigro P, Pompilio G, Capogrossi MC. Cyclophilin a: a key player for human disease. Cell Death Dis (2013) 4:e888. doi:&#xa0;10.1038/cddis.2013.410</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2013.410</ArticleId><ArticleId IdType="pmc">PMC3920964</ArticleId><ArticleId IdType="pubmed">24176846</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu QQ, Cheng A, Wang Y, Li H, Hu L, Zhao X, et al. . Cytokines and their relationship with the severity and prognosis of coronavirus disease 2019 (COVID-19): a retrospective cohort study. BMJ Open (2020) 10:e041471. doi:&#xa0;10.1136/bmjopen-2020-041471</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-041471</ArticleId><ArticleId IdType="pmc">PMC7705426</ArticleId><ArticleId IdType="pubmed">33257492</ArticleId></ArticleIdList></Reference><Reference><Citation>Softic L, Brillet R, Berry F, Ahnou N, Nevers Q, Morin-Dewaele M, et al. . Inhibition of SARS-CoV-2 infection by the cyclophilin inhibitor alisporivir (Debio 025). Antimicrob Agents Chemother (2020) 64(7):e00876-20. doi:&#xa0;10.1128/AAC.00876-20</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00876-20</ArticleId><ArticleId IdType="pmc">PMC7318051</ArticleId><ArticleId IdType="pubmed">32376613</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaushik DK, Hahn JN, Yong VW. EMMPRIN, an upstream regulator of MMPs, in CNS biology. Matrix Biol (2015) 44&#x2013;46:138&#x2013;46. doi:&#xa0;10.1016/j.matbio.2015.01.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.matbio.2015.01.018</ArticleId><ArticleId IdType="pubmed">25644103</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan QW, Yuasa S, Kuno N, Senda T, Kobayashi M, Muramatsu T, et al. . Expression of basigin, a member of the immunoglobulin superfamily, in the mouse central nervous system. Neurosci Res (1998) 30:53&#x2013;63. doi: 10.1016/S0168-0102(97)00119-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0168-0102(97)00119-3</ArticleId><ArticleId IdType="pubmed">9572580</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Zhou L, Bao L, Liu J, Zhu H, Lv Q, et al. . SARS-CoV-2 crosses the blood-brain barrier accompanied with basement membrane disruption without tight junctions alteration. Signal Trans Target Ther (2021) 6:337. doi:&#xa0;10.1038/s41392-021-00719-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00719-9</ArticleId><ArticleId IdType="pmc">PMC8419672</ArticleId><ArticleId IdType="pubmed">34489403</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbott NJ. Astrocyte-endothelial interactions and blood-brain barrier permeability. J Anat (2002) 200:629&#x2013;38. doi:&#xa0;10.1046/j.1469-7580.2002.00064.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1469-7580.2002.00064.x</ArticleId><ArticleId IdType="pmc">PMC1570746</ArticleId><ArticleId IdType="pubmed">12162730</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Z, Wang KKW. Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker. Trends Neurosci (2015) 38:364&#x2013;74. doi:&#xa0;10.1016/j.tins.2015.04.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2015.04.003</ArticleId><ArticleId IdType="pmc">PMC4559283</ArticleId><ArticleId IdType="pubmed">25975510</ArticleId></ArticleIdList></Reference><Reference><Citation>Janigro D, Mondello S, Posti JP, Unden J. GFAP and S100B: What you always wanted to know and never dared to ask. Front Neurol (2022) 13:835597. doi:&#xa0;10.3389/fneur.2022.835597</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2022.835597</ArticleId><ArticleId IdType="pmc">PMC8977512</ArticleId><ArticleId IdType="pubmed">35386417</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham NSN, Zimmerman KA, Moro F, Heslegrave A, Maillard SA, Bernini A, et al. . Axonal marker neurofilament light predicts long-term outcomes and progressive neurodegeneration after traumatic brain injury. Sci Transl Med (2021), 13(613):eabg9922. doi:&#xa0;10.1126/scitranslmed.abg9922</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abg9922</ArticleId><ArticleId IdType="pubmed">34586833</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M-H, Perl DP, Nair G, Li W, Maric D, Murray H, et al. . Microvascular injury in the brains of patients with covid-19. N Engl J Med (2021) 384:481&#x2013;3. doi:&#xa0;10.1056/NEJMc2033369</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2033369</ArticleId><ArticleId IdType="pmc">PMC7787217</ArticleId><ArticleId IdType="pubmed">33378608</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanda T. Biology of the blood-nerve barrier and its alteration in immune mediated neuropathies. J Neurol Neurosurg Psychiatry (2013) 84:208&#x2013;12. doi:&#xa0;10.1136/jnnp-2012-302312</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2012-302312</ArticleId><ArticleId IdType="pubmed">23243216</ArticleId></ArticleIdList></Reference><Reference><Citation>Errede M, Annese T, Petrosino V, Longo G, Girolamo F, de Trizio I, et al. . Microglia-derived CCL2 has a prime role in neocortex neuroinflammation. Fluids Barriers CNS (2022) 19:68. doi:&#xa0;10.1186/s12987-022-00365-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12987-022-00365-5</ArticleId><ArticleId IdType="pmc">PMC9429625</ArticleId><ArticleId IdType="pubmed">36042496</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. . Clinical features of patients infected with 2019 novel coronavirus in wuhan, China. Lancet (2020) 395:497&#x2013;506. doi:&#xa0;10.1016/S0140-6736(20)30183-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry (2019) 90:870&#x2013;81. doi:&#xa0;10.1136/jnnp-2018-320106</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-320106</ArticleId><ArticleId IdType="pubmed">30967444</ArticleId></ArticleIdList></Reference><Reference><Citation>Verde F, Steinacker P, Weishaupt JH, Kassubek J, Oeckl P, Halbgebauer S, et al. . Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (2019) 90:157&#x2013;64. doi:&#xa0;10.1136/jnnp-2018-318704</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-318704</ArticleId><ArticleId IdType="pubmed">30309882</ArticleId></ArticleIdList></Reference><Reference><Citation>Falzone YM, Domi T, Mandelli A, Pozzi L, Schito P, Russo T, et al. . Integrated evaluation of a panel of neurochemical biomarkers to optimize diagnosis and prognosis in amyotrophic lateral sclerosis. Eur J Neurol (2022) 29(7):1930&#x2013;9. doi:&#xa0;10.1111/ene.15321</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.15321</ArticleId><ArticleId IdType="pmc">PMC9314044</ArticleId><ArticleId IdType="pubmed">35263489</ArticleId></ArticleIdList></Reference><Reference><Citation>Gissl&#xe9;n M, Price RW, Andreasson U, Norgren N, Nilsson S, Hagberg L, et al. . Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: A cross-sectional study. EBioMedicine (2016) 3:135&#x2013;40. doi:&#xa0;10.1016/j.ebiom.2015.11.036</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2015.11.036</ArticleId><ArticleId IdType="pmc">PMC4739412</ArticleId><ArticleId IdType="pubmed">26870824</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterson J, Gisslen M, Zetterberg H, Fuchs D, Shacklett BL, Hagberg L, et al. . Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection. PloS One (2014) 9:e116081. doi:&#xa0;10.1371/journal.pone.0116081</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0116081</ArticleId><ArticleId IdType="pmc">PMC4277428</ArticleId><ArticleId IdType="pubmed">25541953</ArticleId></ArticleIdList></Reference><Reference><Citation>Yilmaz A, Blennow K, Hagberg L, Nilsson S, Price RW, Schouten J, et al. . Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls. Expert Rev Mol Diagn (2017) 17:761&#x2013;70. doi:&#xa0;10.1080/14737159.2017.1341313</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14737159.2017.1341313</ArticleId><ArticleId IdType="pubmed">28598205</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondal S, Adhikari N, Banerjee S, Amin SA, Jha T. Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview. Eur J Med Chem (2020) 194:112260. doi:&#xa0;10.1016/j.ejmech.2020.112260</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2020.112260</ArticleId><ArticleId IdType="pubmed">32224379</ArticleId></ArticleIdList></Reference><Reference><Citation>Bian H, Zheng Z-H, Wei D, Wen A, Zhang Z, Lian J-Q, et al. . Safety and efficacy of meplazumab in healthy volunteers and COVID-19 patients: a randomized phase 1 and an exploratory phase 2 trial. Signal Trans Target Ther (2021) 6:194. doi:&#xa0;10.1038/s41392-021-00603-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00603-6</ArticleId><ArticleId IdType="pmc">PMC8127508</ArticleId><ArticleId IdType="pubmed">34001849</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Cubillo B, de la Higuera MAM, Lucena R, Franci EV, Hurtado M, Romero NC, et al. . Should cyclosporine be useful in renal transplant recipients affected by SARS-CoV-2? Am J Transplant (2020) 20:3173&#x2013;81. doi:&#xa0;10.1111/ajt.16141</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.16141</ArticleId><ArticleId IdType="pmc">PMC7307110</ArticleId><ArticleId IdType="pubmed">32529737</ArticleId></ArticleIdList></Reference><Reference><Citation>McArthur S, Loiola RA, Maggioli E, Errede M, Virgintino D, Solito E. The restorative role of annexin A1 at the blood&#x2013;brain barrier. Fluids Barriers CNS (2016) 13:17. doi:&#xa0;10.1186/s12987-016-0043-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12987-016-0043-0</ArticleId><ArticleId IdType="pmc">PMC5031267</ArticleId><ArticleId IdType="pubmed">27655189</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheikh MH, Errede M, d&#x2019;Amati A, Khan NQ, Fanti S, Loiola RA, et al. . Impact of metabolic disorders on the structural, functional, and immunological integrity of the blood-brain barrier: Therapeutic avenues. FASEB J (2022) 36(1):e22107. doi:&#xa0;10.1096/fj.202101297R</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.202101297R</ArticleId><ArticleId IdType="pubmed">34939700</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzolini E, Levi R, Sarti R, Pozzi C, Mollura M, Mantovani A, et al. . Association between BNT162b2 vaccination and long COVID after infections not requiring hospitalization in health care workers. JAMA (2022) 328:676. doi:&#xa0;10.1001/jama.2022.11691</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.11691</ArticleId><ArticleId IdType="pmc">PMC9250078</ArticleId><ArticleId IdType="pubmed">35796131</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte KI, Catahay JA, Velasco JV, Pastrana A, Ver AT, Pangilinan FC, et al. . Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review. eClinicalMedicine (2022) 53:101624. doi:&#xa0;10.1016/j.eclinm.2022.101624</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101624</ArticleId><ArticleId IdType="pmc">PMC9417563</ArticleId><ArticleId IdType="pubmed">36051247</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>